share_log

HC Wainwright & Co. Maintains Buy on ATAI Life Sciences, Lowers Price Target to $10

Benzinga ·  Nov 19 01:46  · Ratings

HC Wainwright & Co. analyst Patrick Trucchio maintains ATAI Life Sciences (NASDAQ:ATAI) with a Buy and lowers the price target from $15 to $10.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment